Advanced in Virilizing Ovarian Tumor

Dr. Joseph Z. Ye

Oncology | Hematology
American Oncology Partners PA
420 Mcphee Rd Sw, Suite A, 
Olympia, WA 
 (2242.4 mi)
Accepting New Patients
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
American Oncology Partners PA
420 Mcphee Rd Sw, Suite A, 
Olympia, WA 
 (2242.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Joseph Ye is an Oncologist and a Hematologist in Olympia, Washington. Dr. Ye and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Ye is currently accepting new patients.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
Capital Medical Center
Mason General Hospital & Family Of Clinics
Providence Centralia Hospital
Providence St Peter Hospital
Languages Spoken
English
Castilian
French
Hebrew
Mandarin
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource
  •  Premera
  •  Humana

Locations

AMERICAN ONCOLOGY PARTNERS PA
420 Mcphee Rd Sw, Suite A, Olympia, WA 98502

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2024
Intervention Type: Drug
Study Drug: Abexinostat
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Enrollment Status: Completed
Publish Date: August 13, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials
Similar Doctors
Advanced in Virilizing Ovarian Tumor
Dr. James J. Lechner
Oncology | Hematology
Advanced in Virilizing Ovarian Tumor
Dr. James J. Lechner
Oncology | Hematology

Providence Health And Services Washington

4525 3rd Ave Se, Suite 200, 
Lacey, WA 
 (6.0 mi)
360-754-3934
Languages Spoken:
English, Hindi, Hungarian, Korean, Polish, Portuguese, Russian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

James Lechner is an Oncologist and a Hematologist in Lacey, Washington. Dr. Lechner and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Waldenstrom Macroglobulinemia. Dr. Lechner is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology
Distinguished in Virilizing Ovarian Tumor
Dr. Andrea L. Veatch
Hematology Oncology | Oncology | Hematology

Northwest Medical Specialties PLLC

34509 9th Ave S, Suite 107, 
Federal Way, WA 
 (34.0 mi)
253-428-8700
Languages Spoken:
English, French, Konkani, Malayalam, Spanish, Turkish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrea Veatch is a Hematologist Oncology specialist and an Oncologist in Federal Way, Washington. Dr. Veatch and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Testicular Yolk Sac Tumor, and Virilizing Ovarian Tumor. Dr. Veatch is currently accepting new patients.

Advanced in Virilizing Ovarian Tumor
Dr. Monique C. Semien
Hematology Oncology | Hematology | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Monique C. Semien
Hematology Oncology | Hematology | Oncology

Kaiser Foundation Health Plan Of Washington

700 Lilly Rd Ne, 
Olympia, WA 
 (5.3 mi)
360-923-7000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Monique Semien is a Hematologist Oncology specialist and a Hematologist in Olympia, Washington. Dr. Semien and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, Lung Cancer, and Paget Disease of the Breast. Dr. Semien is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile